The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis

Surgeon

Volumn 14, Issue 6, 2016, Pages 327-336

  Wrafter, Paula F ^a   Connelly, Tara M ^b   Khan, Jody ^c   Devane, Liam ^d   Kelly, John ^e   Joyce, William P ^a,f  

^a Galway Clinic   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c BEAUMONT HOSPITAL   (Ireland)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e MAYO GENERAL HOSPITAL   (Ireland)

^f ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Bibliometric analysis; Colon cancer; Colorectal cancer; Colorectal carcinoma; Rectal cancer

Indexed keywords

BIBLIOMETRICS; CARCINOMA; COLON TUMOR; COLONOSCOPY; HUMAN; RECTUM TUMOR;

BIBLIOMETRICS; CARCINOMA; COLONIC NEOPLASMS; COLONOSCOPY; HUMANS; RECTAL NEOPLASMS;

EID: 84963682499     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surge.2016.03.001     Document Type: Review

References (109)

1. 1 The World Health Organisation, World cancer report 2014., 2014 http://w2.iarc.fr/en/publications/books/wcr/ [accessed 01.08.15].
2. 2 Loonen, M.P., Hage, J.J., Kon, M., Plastic surgery classics: characteristics of 50 top-cited articles in four plastic surgery journals since 1946. Plast Reconstr Surg 121 (2008), 320e–327e.
3. 3 Dubin, D., Hafner, A.W., Arndt, K.A., Citation classics in clinical dermatologic journals. Citation analysis, biomedical journals, and landmark articles, 1945–1990. Arch Dermatol 129 (1993), 1121–1129.
4. 4 Joyce, C.W., Kelly, J.C., Sugrue, C., A bibliometric analysis of the 100 most influential papers in burns. Burns J Int Soc Burn Inj 40 (2014), 30–37.
5. 5 Paladugu, R., Schein, M., Gardezi, S., Wise, L., One hundred citation classics in general surgical journals. World J Surg 26 (2002), 1099–1105.
6. 6 Kelly, J.C., Glynn, R.W., O'Briain, D.E., Felle, P., McCabe, J.P., The 100 classic papers of orthopaedic surgery: a bibliometric analysis. J Bone Jt Surg Br Vol 92:10 (2010), 1338–1343.
7. 7 Kavanagh, R.G., Kelly, J.C., Kelly, P.M., Moore, D.P., The 100 classic papers of pediatric orthopaedic surgery: a bibliometric analysis. J Bone Jt Surg Am Vol, 95, 2013, e134.
8. 8 Fearon, E.R., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61:5 (1990), 759–767.
9. 9 Ekbom, A., Helmick, C., Zack, M., Adami, H., Ulcerative-colitis and colorectal-cancer – a population-based study. N Engl J Med 323 (1990), 1228–1233.
10. 10 Burkitt, D.P., Epidemiology of cancer of colon and rectum. Cancer, 28, 1971, 3.
11. 11 Van Cutsem, E., Kohne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009), 1408–1417.
12. 12 Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., Fuhrer, P., Colorectal-carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 5 (1979), 957–972.
13. 13 Thun, M.J., Namboodiri, M.M., Heath, C.W., Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325 (1991), 1593–1596.
14. 14 Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
15. 15 Barker, N., van Es, J.H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature, 449, 2007 1003–U1.
16. 16 Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988), 525–532.
17. 17 Winawer, S.J., Fletcher, R.H., Miller, L., et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112:2 (1997), 594–642.
18. 18 Kinzler, K.W., Vogelstein, B., Lessons from hereditary colorectal cancer. Cell 87 (1996), 159–170.
19. 19 Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., et al. Mutations of chromosome-5q21 genes in Fap and colorectal-cancer patients. Science 253 (1991), 665–669.
20. 20 Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004), 337–345.
21. 21 Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004), 2343–2351.
22. 22 Boland, C.R., Thibodeau, S.N., Hamilton, S.R., Sidransky, D., Eshleman, J.R., Burt, R.W., et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998), 5248–5257.
23. 23 Vasen, H.F.A., Mecklin, J.P., Khan, P.M., Lynch, H.T., The International-Collaborative-Group-On-Hereditary-Non-Polyposis-Colorectal-Cancer (ICG-HNPCC). Dis Colon Rectum 34 (1991), 424–425.
24. 24 Tetsu, O., McCormick, F., beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398 (1999), 422–426.
25. 25 Nelson, H., Sargent, D., Wieand, H.S., Fleshman, J., Anvari, M., Stryker, S.J., et al. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 350:20 (2004), 2050–2059.
26. 26 Thibodeau, S.N., Bren, G., Schaid, D., Microsatellite instability in cancer of the proximal colon. Science 260 (1993), 816–819.
27. 27 Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
28. 28 Aaltonen, L.A., Peltomaki, P., Leach, F.S., Sistonen, P., Pylkkanen, L., Mecklin, J.P., et al. Clues to the pathogenesis of familial colorectal-cancer. Science 260 (1993), 812–816.
29. 29 Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J.G., Baylin, S.B., Issa, J.P.J., CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96 (1999), 8681–8686.
30. 30 Winawer, S.J., Zauber, A.G., Ho, M.N., Obrien, M.J., Gottlieb, L.S., Sternberg, S.S., et al. Prevention of colorectal-cancer by colonoscopic polypectomy. N Engl J Med 329 (1993), 1977–1981.
31. 31 Hidalgo, I.J., Raub, T.J., Borchardt, R.T., Characterization of the human-colon carcinoma cell-line (CACO-2) as a model system for intestinal epithelial permeability. Gastroenterology 96 (1989), 736–749.
32. 32 Korinek, V., Barker, N., Morin, P.J., vanWichen, D., deWeger, R., Kinzler, K.W., et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC(−/−) colon carcinoma. Science 275 (1997), 1784–1787.
33. 33 Winawer, S., Fletcher, R., Rex, D., Bond, J., Burt, R., Ferrucci, J., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale – update based on new evidence. Gastroenterology 124 (2003), 544–560.
34. 34 Fishel, R., Lescoe, M.K., Rao, M.R.S., Copeland, N.G., Jenkins, N.A., Garber, J., et al. The human mutator gene homolog Msh2 and its association with hereditary nonpolyposis colon-cancer. Cell 75:5 (1993), 1027–1038.
35. 35 Selby, J.V., Friedman, G.D., Quesenberry, C.P., Weiss, N.S., A case control study of screening sigmoidoscopy and mortality from colorectal-cancer. N Engl J Med 326 (1992), 653–657.
36. 36 de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000), 2938–2947.
37. 37 Vogelstein, B., Fearon, E.R., Kern, S.E., Hamilton, S.R., Preisinger, A.C., Nakamura, Y., et al. Allelotype of colorectal carcinomas. Science 244 (1989), 207–211.
38. 38 Sauer, R., Becker, H., Hohenberger, W., Rodel, C., Wittekind, C., Fietkau, R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004), 1731–1740.
39. 39 Ionov, Y., Peinado, M.A., Malkhosyan, S., Shibata, D., Perucho, M., Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (1993), 558–561.
40. 40 Powell, S.M., Zilz, N., Beazerbarclay, Y., Bryan, T.M., Hamilton, S.R., Thibodeau, S.N., et al. APC mutations occur early during colorectal tumorigenesis. Nature 359 (1992), 235–237.
41. 41 Mandel, J.S., Bond, J.H., Church, T.R., Snover, D.C., Bradley, G.M., Schuman, L.M., et al. Reducing mortality from colorectal-cancer by screening for fecal occult blood. N Engl J Med 328 (1993), 1365–1371.
42. 42 Hastie, N.D., Dempster, M., Dunlop, M.G., Thompson, A.M., Green, D.K., Allshire, R.C., Telomere reduction in human colorectal-carcinoma and with aging. Nature 346 (1990), 866–868.
43. 43 Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., et al. Identification and characterization of the familial adenomatous polyposis-coli gene. Cell 66 (1991), 589–600.
44. 44 Steinmetz, K.A., Potter, J.D., Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 96 (1996), 1027–1039.
45. 45 Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000), 905–914.
46. 46 Herman, J.G., Umar, A., Polyak, K., Graff, J.R., Ahuja, N., Issa, J.P.J., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95 (1998), 6870–6875.
47. 47 Leach, F.S., Nicolaides, N.C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., et al. Mutations of a MUTS homolog in hereditary nonpolyposis colorectal-cancer. Cell 75 (1993), 1215–1225.
48. 48 Krook, J.E., Moertel, C.G., Gunderson, L.L., Wieand, H.S., Collins, R.T., Beart, R.W., et al. Effective surgical adjuvant therapy for high-risk rectal-carcinoma. N Engl J Med 324 (1991), 709–715.
49. 49 Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000), 1041–1047.
50. 50 Giardiello, F.M., Hamilton, S.R., Krush, A.J., Piantadosi, S., Hylind, L.M., Celano, P., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328 (1993), 1313–1316.
51. 51 Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., et al. Suppression of intestinal polyposis in Apc(Delta 716) knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996), 803–809.
52. 52 Nicolaides, N.C., Papadopoulos, N., Liu, B., Wei, Y.F., Carter, K.C., Ruben, S.M., et al. Mutations of 2 Pms homologs in hereditary nonpolyposis colon-cancer. Nature 371 (1994), 75–80.
53. 53 Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L.Z., Lutterbaugh, J., et al. Inactivation of the type-Ii Tgf-beta receptor in colon-cancer cells with microsatellite instability. Science 268 (1995), 1336–1338.
54. 54 Goldberg, R.M., Sargent, D.J., Morton, R.F., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004), 23–30.
55. 55 Eberhart, C.E., Coffey, R.J., Radhika, A., Giardiello, F.M., Ferrenbach, S., Dubois, R.N., Up-regulation of cyclooxygenase-2 gene-expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994), 1183–1188.
56. 56 Lengauer, C., Kinzler, K.W., Vogelstein, B., Genetic instability in colorectal cancers. Nature 386 (1997), 623–627.
57. 57 Kapiteijn, E., Marijnen, C.A.M., Nagtegaal, I.D., Putter, H., Steup, W.H., Wiggers, T., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 (2001), 638–646.
58. 58 Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004), 285–296.
59. 59 O'Brien, C.A., Pollett, A., Gallinger, S., Dick, J.E., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007), 106–110.
60. 60 Vasen, H.F.A., Watson, P., Mecklin, J.P., Lynch, H.T., Icg, H., New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116 (1999), 1453–1456.
61. 61 Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M., et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 (2000), 78–85.
62. 62 Pahlman, L., Glimelius, B., Cedermark, B., Lundell, G., Rubio, C., Rutqvist, L.E., et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336 (1997), 980–987.
63. 63 Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006), 268–274.
64. 64 van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111 (2002), 241–250.
65. 65 Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., DuBois, R.N., Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 9 (1998), 705–716.
66. 66 Willett, C.G., Boucher, Y., di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004), 145–147.
67. 67 Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K.V., Vogelstein, B., Suppression of human colorectal-carcinoma cell-growth by wild-type-P53. Science 249 (1990), 912–915.
68. 68 Umar, A., Boland, C.R., Terdiman, J.P., Syngal, S., de la Chapelle, A., Ruschoff, J., et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004), 261–268.
69. 69 Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445 (2007), 111–115.
70. 70 Pickhardt, P.J., Choi, J.R., Hwang, I., Butler, J.A., Puckett, M.L., Hildebrandt, H.A., et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349 (2003), 2191–2200.
71. 71 Baker, S.J., Fearon, E.R., Nigro, J.M., Hamilton, S.R., Preisinger, A.C., Jessup, J.M., et al. Chromosome-17 deletions and P53 gene-mutations in colorectal carcinomas. Science 244 (1989), 217–221.
72. 72 Saltz, L.B., Meropol, N.J., Loehrer, P.J., Needle, M.N., Kopit, J., Mayer, R.J., Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004), 1201–1208.
73. 73 Kinzler, K.W., Nilbert, M.C., Su, L.K., Vogelstein, B., Bryan, T.M., Levy, D.B., et al. Identification of Fap locus genes from chromosome-5Q21. Science 253 (1991), 661–665.
74. 74 Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003), 60–65.
75. 75 Bronner, C.E., Baker, S.M., Morrison, P.T., Warren, G., Smith, L.G., Lescoe, M.K., et al. Mutation in the DNA mismatch repair gene homolog hMLH1 is associated with hereditary nonpolyposis colon-cancer. Nature 368 (1994), 258–261.
76. 76 Lacy, A.M., Garcia-Valdecasas, J.C., Delgado, S., Castells, A., Taura, P., Pique, J.M., et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 359 (2002), 2224–2229.
77. 77 Fearon, E.R., Cho, K.R., Nigro, J.M., Kern, S.E., Simons, J.W., Ruppert, J.M., et al. Identification of a chromosome-18q gene that is altered in colorectal cancers. Science 247 (1990), 49–56.
78. 78 Tsujii, M., Kawano, S., DuBois, R.N., Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94 (1997), 3336–3340.
79. 79 Hardcastle, J.D., Chamberlain, J.O., Robinson, M.H.E., Moss, S.M., Amar, S.S., Balfour, T.W., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (1996), 1472–1477.
80. 80 Quirke, P., Durdey, P., Dixon, M.F., Williams, N.S., Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 2 (1986), 996–999.
81. 81 Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Goodman, P.J., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon-carcinoma. N Engl J Med 322 (1990), 352–358.
82. 82 Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004), 391–400.
83. 83 Bos, J.L., Fearon, E.R., Hamilton, S.R., Verlaandevries, M., Vanboom, J.H., Vandereb, A.J., et al. Prevalence of RAS gene-mutations in human colorectal cancers. Nature 327 (1987), 293–297.
84. 84 Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S.H., Masiarz, F.R., et al. Association of the APC gene-product with beta-catenin. Science 262 (1993), 1731–1734.
85. 85 Muto, T., Bussey, H.J.R., Morson, B., Evolution of cancer of colon and rectum. Cancer 36 (1975), 2251–2270.
86. 86 Heald, R.J., Husband, E.M., Ryall, R.D.H., The mesorectum in rectal-cancer surgery – the clue to pelvic recurrence. Br J Surg 69 (1982), 613–616.
87. 87 Pinto, M., Robineleon, S., Appay, M.D., Kedinger, M., Triadou, N., Dussaulx, E., et al. Enterocyte-like differentiation and polarization of the human-colon carcinoma cell-line Caco-2 in culture. Biol Cell 47 (1983), 323–330.
88. 88 Papadopoulos, N., Nicolaides, N.C., Wei, Y.F., Ruben, S.M., Carter, K.C., Rosen, C.A., et al. Mutation of a Mutl homolog in hereditary colon-cancer. Science 263 (1994), 1625–1629.
89. 89 Eaden, J.A., Abrams, K.R., Mayberry, J.F., The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001), 526–535.
90. 90 Steinbach, G., Lynch, P.M., Phillips, R.K.S., Wallace, M.H., Hawk, E., Gordon, G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000), 1946–1952.
91. 91 Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J.C., et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275 (1997), 967–969.
92. 92 Fong, Y., Fortner, J., Sun, R.L., Brennan, M.F., Blumgart, L.H., Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer – analysis of 1001 consecutive cases. Ann Surg 230 (1999), 309–318.
93. 93 Guillou, P.J., Quirke, P., Thorpe, H., Walker, J., Jayne, D.G., Smith, A.M.H., et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 365 (2005), 1718–1726.
94. 94 Kronborg, O., Fenger, C., Olsen, J., Jorgensen, O.D., Sondergaard, O., Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (1996), 1467–1471.
95. 95 Giantonio, B.J., Catalano, P.J., Meropol, N.J., O'Dwyer, P.J., Mitchell, E.P., Alberts, S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007), 1539–1544.
96. 96 Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007), 1108–1113.
97. 97 Saltz, L.B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26 (2008), 2013–2019.
98. 98 Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O'Callaghan, C.J., Tu, D., Tebbutt, N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008), 1757–1765.
99. 99 Heald, R.J., Ryall, R., Recurrence and survival after total mesorectal excision for rectal-cancer. Lancet 1 (1986), 1479–1482.
100. 100 Tournigand, C., Andre, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004), 229–237.
101. 101 Lieberman, D.A., Weiss, D.G., Bond, J.H., Ahnen, D.J., Garewal, H., Chejfec, G., et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med 343 (2000), 162–168.
102. 102 Karin, M., Cao, Y.X., Greten, F.R., Li, Z.W., NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 (2002), 301–310.
103. 103 Scheele, J., Stang, R., Altendorfhofmann, A., Paul, M., Resection of colorectal liver metastases. World J Surg 19 (1995), 59–71.
104. 104 Andersen, C.L., Jensen, J.L., Orntoft, T.F., Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64 (2004), 5245–5250.
105. 105 Kane, M.F., Loda, M., Gaida, G.M., Lipman, J., Mishra, R., Goldman, H., et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57 (1997), 808–811.
106. 106 Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 1626–1634.
107. 107 Zhong, H., De Marzo, A.M., Laughner, E., Lim, M., Hilton, D.A., Zagzag, D., et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59 (1999), 5830–5835.
108. 108 Wrafter, P., Connelly, T., Khan, J., Devane, L., Kelly, J.C., Joyce, W.P., The top 100 influential manuscripts in colorectal cancer; a bibliometric analysis. Ir J Med Sci 184:Suppl. 9 (September 2015), 361–421.
109. 109 Garfield, E., Journal impact factor: a brief review. CMAJ 161 (1999), 979–980.